Polymer-VWF conjugates extend circulating protein half-life, reducing dosing frequency for bleeding disorder treatment.
Fusion of half-life enhancing polypeptides to coagulation factors extends plasma circulation time, reducing infusion frequency for hemophilia treatment.
Mutated ADAMTS13 polypeptide substrate eliminates autofluorescence noise from FRETS-VWF73, delivering linear calibration curves for accurate TTP diagnosis.
A haemostatic composition combines gelatine with hyaluronic acid to enhance bleeding control and absorption properties.